Nuvation Bio Inc. Class A Common Stock vs Zeta Global Holdings Corp — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5.04 (market cap $1.74B), while Zeta Global Holdings Corp trades at $33.35 (market cap $8.29B). The key difference: Zeta Global Holdings Corp is far larger — about 4.8× Nuvation Bio Inc. Class A Common Stock's market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Zeta Global Holdings Corp for 18 Days on average.
| NUVB | ZETA | |
|---|---|---|
Market Cap | $1.74B | $8.29B |
Volume | 9,289,619 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $9.54 | $33.74 |
52-Week Low | $3.41 | $14.55 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $1.33B | $8.18B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZETA trades at $33.74, showing strong technical momentum with a bullish moving average signal and trading near resistance at $34. The company demonstrates solid revenue growth with Q2 2026 revenue reaching $1.6B and has beaten earnings estimates for three consecutive quarters. Recent expansion into the UK market and AI platform adoption are driving investor optimism, though negative net margins and high valuation multiples warrant caution.
ZETA presents a growth opportunity with strong analyst support (75% buy ratings) and AI-driven business expansion, but faces execution risks from negative profitability and elevated valuation metrics. The stock's current price above the $32.40 consensus target suggests near-term consolidation potential amid ongoing business transformation efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →